The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The most promising novel approaches currently in development for MPNs
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, briefly comments on the promising novel approaches in development for myeloproliferative neoplasms (MPNs), highlighting the potential of targeted therapies such as specific JAK inhibitors and treatments targeting mutant calreticulin (CALR). This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’m particularly excited about the variety of agents that are more targeted than they have been in the past. We have known about the driver mutations in MPNs for a long time and we’ve had some degree of targeting in the era of JAK inhibition, although those have been non-selective JAK inhibitors, they’ve made a big impact, but still, they’re not necessarily specific for the mutated form...
I’m particularly excited about the variety of agents that are more targeted than they have been in the past. We have known about the driver mutations in MPNs for a long time and we’ve had some degree of targeting in the era of JAK inhibition, although those have been non-selective JAK inhibitors, they’ve made a big impact, but still, they’re not necessarily specific for the mutated form. So we have two more specific JAK inhibitors from Incyte and Ajax early in testing, and now we have multiple approaches that are much more specific for CALR, whether it’s CAR-T, vaccines, or agents now both from Incyte and JNJ in clinical trials. So we’re hopeful that probably even in combination with the benefits we’ve seen with other agents, we know the JAK inhibitors are clearly beneficial – you pick which one is the best for the patient based on the profile. Interferons clearly have a role. Hopefully, with these additional targeted agents, we’ll be able to get to deeper settings of remission and potentially even think about minimal residual disease. How do we even find our way to a cure?
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
